Replies to post #207148 on Biotech Values

[DewDiligence]

If FoBs follow the 20% or so discount to the branded product that would still seem attractive pricing potential for HIF drugs with the added benefit of being Oral, maybe alleviate the need for Iron and possible safety advantage.

If there are multiple FoBs for a given drug in a given market, the price erosion will likely be much more than 20%. Look at the US market for Lovenox as an example of how bad things can get with multiple players.

Nevertheless, I'm not opining that the HIF drugs are a bad business proposition.